Notably, these findings suggest that MIF+ tumor cells infiltrating TLS, rather than TLS status alone, may serve as a co-factor for evaluating immunotherapy response, a phenomenon detectable even in baseline tumors of ESCC non-responders. Here, MIF is linked to neoplasm.